Label evidence
Tirzepatide side effects
Tirzepatide is the active ingredient in Zepbound and Mounjaro. Their adverse-reaction sections describe gastrointestinal symptoms and other reported events, but the percentages belong to specific study populations. This page uses the label tables directly and identifies the study context beside the numbers. It does not combine the two brands into a single personal risk estimate or infer a diagnosis from an app record. Zepbound labelMounjaro label
Sources checked
What the Zepbound table actually reports
The Zepbound table pools Study 1 and Study 2 in adults with obesity or overweight. Nausea was reported by 25%, 29%, and 28% at the 5, 10, and 15 mg assigned doses, compared with 8% on placebo. Constipation was reported by 17%, 14%, and 11%, compared with 5% on placebo. These percentages describe study participants with reported events, not how often a given person experienced a symptom. Zepbound label
The table also includes vomiting, diarrhea, fatigue, and hair loss. Its fatigue category groups several related terms, including asthenia, lethargy, and malaise. Its constipation category includes hard stools. A short symptom name in a chart therefore has a definition behind it. Reading the footnotes helps avoid treating the label category as one narrowly defined everyday description. Zepbound label
| Reaction | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Fatigue | 3% | 5% | 6% | 7% |
| Hair loss | 1% | 5% | 4% | 5% |
Mounjaro data has a different study context
Mounjaro section 6.1 reports pooled placebo-controlled adult type 2 diabetes studies: SURPASS-1 (monotherapy) and SURPASS-5 (with basal insulin), described in sections 14.2 and 14.4. Nausea was reported by 12%, 15%, and 18% at 5, 10, and 15 mg, versus 4% on placebo. Constipation was 6%, 6%, and 7%, versus 1%. These are not the Zepbound weight-management population. Mounjaro label
The Mounjaro label cautions that adverse-reaction rates from differently conducted studies cannot be directly compared and may not reflect rates in practice. That limitation is important when two tables share dose strengths. A lower percentage in one study is not enough to conclude that one branded presentation causes fewer symptoms for an individual reader. Mounjaro label
Timing and reporting limits
In the pooled Zepbound Study 1 and Study 2 data, the majority of nausea, vomiting, and diarrhea events occurred during escalation and decreased over time. The Mounjaro adult pooled studies describe a similar pattern for those three symptoms. That wording is specific: it does not state that every adverse reaction follows the same timing, or that a new symptom outside escalation is explained by the medicine. Zepbound labelMounjaro label
Postmarketing sections describe voluntarily reported events from a population of uncertain size. The labels state that frequency cannot always be reliably estimated or a causal relationship established from those reports. A postmarketing list and a controlled-study percentage answer different questions, so this page does not turn a reported event into an invented percentage. Zepbound labelMounjaro label
Keep the date and observation together
PinPoint supports side-effect entries with severity ratings and daily notes, alongside injection dates, doses, sites, and pain levels. This can preserve an observation and the surrounding dose history without making a medical judgment. Export in PDF, CSV, or JSON offers a way to review what was recorded rather than relying on a recollection of which week it occurred. App features
A modeled-level curve is a mathematical visualization, not a measurement or a causal test. The app description identifies population-average half-life data and individual-variation limits. A note occurring near a modeled peak therefore remains a dated note; the app does not establish that the peak explains it. Talk to the prescriber about new, persistent, or concerning symptoms. App features
Useful distinctions
Questions
Are side-effect percentages the same for both tirzepatide brands?
No. The label tables describe different populations and study settings. The Zepbound table cited here pools Study 1 and Study 2; the Mounjaro table pools adult placebo-controlled diabetes studies. Zepbound labelMounjaro label
Does a logged symptom prove tirzepatide caused it?
A log records timing and an observation. PinPoint supports that documentation but is not a diagnostic tool; the label data also has study and reporting limits. App featuresZepbound label
Your record, together
Keep the details attached to the date.
Dose history, reminders, daily notes, and the context you choose to record. PinPoint app features.
Get PinPoint on the App StoreSources & scope
Label facts link to the full prescribing information. Product claims use the supplied PinPoint app description. Numerical examples show their assumptions and arithmetic.
- PinPoint feature description
Only feature claims verified against the supplied description. No prices, clinical recommendations or inferred tablet inventory.
- How to read this reference
Editorial organization, explicit scope limits, and interpretation of the cited label or app evidence. No additional medical facts.
- Mounjaro prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
d2d7da5d-ad07-4228-955f-cf7e355c8cc0. - Zepbound prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID:
487cd7e7-434c-4925-99fa-aa80b1cc776b.